Evidence map›Paper›PMID 40742486›Full record

ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2025

Evaluation and comparison of the anti-proliferative and anti-metastatic effects of urolithin A and urolithin B against esophageal cancer cells: an in vitro and in silico study.

Maryam Shojaee, Mehdi Rostami, Mohammad Soukhtanloo, Mohammad Jalili-Nik

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maryam ShojaeeDepartment of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mehdi RostamiDepartment of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad SoukhtanlooDepartment of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Soukhtanloom@mums.ac.ir.
Mohammad Jalili-NikDepartment of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Mohammad.Jalilinik@gmail.com.

Funding

Mashhad University of Medical Sciences Mashhad University of Medical Sciences
6 · The paper itself

Abstract

introductionEsophageal squamous cell carcinoma (ESCC) is a prevalent and lethal cancer, with traditional treatments often ineffective. This study investigates the anti-proliferative and anti-metastatic effects of natural compounds Urolithin A (UA) and Urolithin B (UB) on ESCC cell lines KYSE-30 and YM-1.

methodsKYSE-30 and YM-1 ESCC cells were treated with UA and UB, and their viability assays, cell cycle arrest, apoptosis, expressions of mRNA linked to apoptosis and metastasis, generation of reactive oxygen species (ROS), activity of MMP-2 and MMP-9, along with mRNA expressions of MMP-2 and MMP-9, and migration were assessed.

resultsThe results showed that UA (which had lower IC

conclusionUB and, more potently, UA show the potential to induce apoptosis while reducing metastatic properties and migration of ESCC cells, suggesting them as promising candidates for new anti-ESCC therapies; however, further preclinical and clinical research is needed to fully understand their anti-cancer effects and mechanisms.

Indexed as

Antineoplastic AgentsCoumarinsEsophageal NeoplasmsApoptosisCell Cycle CheckpointsCell Line, TumorCell MovementCell ProliferationCell SurvivalComputer SimulationEsophageal Squamous Cell CarcinomaHumansMatrix Metalloproteinase 2Matrix Metalloproteinase 9Reactive Oxygen Species3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-oneAntineoplastic AgentsCoumarinsMatrix Metalloproteinase 2Matrix Metalloproteinase 9MMP2 protein, humanMMP9 protein, humanReactive Oxygen Speciesurolithin BApoptosisEsophageal cancerEsophageal squamous cell carcinomaMatrix metalloproteinaseMigrationUrolithin AUrolithin B

Identifiers

PMID40742486
PMCPMC12314155

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.